Karyopharm Therapeutics Inc. SEC filings KPTI
Karyopharm Therapeutics Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Apr 2, 2015. Its latest annual report, Form ARS, was filed on Apr 13, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (listing notice). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 13, 2026 | Apr 13, 2026 |
| DEF 14A | Proxy statement | Jan 9, 2026 | Feb 18, 2026 |
| PRE 14A | Preliminary proxy statement | Dec 30, 2025 | Dec 30, 2025 |
| DEFA14A | Additional proxy material | Apr 14, 2025 | — |
| DEF 14A | Proxy statement | Apr 14, 2025 | May 28, 2025 |
| DEF 14A | Proxy statement | Dec 16, 2024 | Jan 30, 2025 |
| PRE 14A | Preliminary proxy statement | Dec 5, 2024 | Dec 5, 2024 |
| DEFA14A | Additional proxy material | Apr 19, 2024 | — |
| DEF 14A | Proxy statement | Apr 19, 2024 | May 29, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 8, 2024 | May 29, 2024 |
| DEFA14A | Additional proxy material | Apr 11, 2023 | — |
| DEF 14A | Proxy statement | Apr 11, 2023 | — |
| PRE 14A | Preliminary proxy statement | Mar 31, 2023 | — |
| DEFA14A | Additional proxy material | May 12, 2022 | — |
| DEFA14A | Additional proxy material | Apr 8, 2022 | — |
| DEF 14A | Proxy statement | Apr 8, 2022 | May 19, 2022 |
| DEFA14A | Additional proxy material | May 3, 2021 | — |
| DEFA14A | Additional proxy material | Apr 7, 2021 | — |
| DEF 14A | Proxy statement | Apr 7, 2021 | May 21, 2021 |
| DEFA14A | Additional proxy material | Apr 9, 2020 | — |
| DEF 14A | Proxy statement | Apr 9, 2020 | May 21, 2020 |
| DEFA14A | Additional proxy material | Apr 19, 2019 | — |
| DEF 14A | Proxy statement | Apr 19, 2019 | Jun 6, 2019 |
| PRE 14A | Preliminary proxy statement | Apr 2, 2019 | Jun 6, 2019 |
| DEFA14A | Additional proxy material | Apr 27, 2018 | — |
| DEF 14A | Proxy statement | Apr 27, 2018 | Jun 19, 2018 |
| DEFA14A | Additional proxy material | Apr 28, 2017 | — |
| DEF 14A | Proxy statement | Apr 28, 2017 | Jun 15, 2017 |
| DEFA14A | Additional proxy material | Apr 29, 2016 | — |
| DEF 14A | Proxy statement | Apr 29, 2016 | Jun 16, 2016 |
| DEFA14A | Additional proxy material | Apr 7, 2015 | — |
| DEF 14A | Proxy statement | Apr 7, 2015 | May 22, 2015 |
Showing 32 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KPTI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newton, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1503802
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.